Nicolas Joram1,2, Erta Beqiri3,4, Stefano Pezzato5, Moscatelli Andrea5, Chiara Robba3, Jean-Michel Liet6, Alexis Chenouard6, Pierre Bourgoin6, Marek Czosnyka3, Pierre-Louis Léger7,8, Peter Smielewski3. 1. Pediatric Intensive Care Unit, University Hospital of Nantes, Nantes, France. nicolas.joram@chu-nantes.fr. 2. INSERM U955-ENVA, University Paris 12, Paris, France. nicolas.joram@chu-nantes.fr. 3. Brain Physics Laboratory, Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK. 4. Department of Physiology and Transplantation, Milan University, Milan, Italy. 5. Neonatal and Pediatric Intensive Care Unit, IRCCS Giannina Gaslini Institute, Genoa, Italy. 6. Pediatric Intensive Care Unit, University Hospital of Nantes, Nantes, France. 7. Pediatric Intensive Care Unit, Trousseau University Hospital, Paris, France. 8. INSERM U955-ENVA, University Paris 12, Paris, France.
Abstract
OBJECTIVE: Cerebral autoregulation (CA) impairment may pose a risk factor for neurological complications among children supported by extracorporeal membrane oxygenation (ECMO). Our first objective was to investigate the feasibility of CA continuous monitoring during ECMO treatment and to describe its evolution over time. The second objective was to analyze the association between CA impairment and neurological outcome. DESIGN: Observational prospective study. PATIENTS AND SETTING: Twenty-nine children treated with veno-arterial or veno-venous ECMO in the PICU of Nantes University Hospital, France, and the PICU of the IRCCS Giannina Gaslini Institute in Genoa, Italy. MEASUREMENTS: A correlation coefficient between the variations of regional cerebral oxygen saturation and the variations of mean arterial blood pressure (MAP) was calculated as an index of CA (cerebral oxygenation reactivity index, COx). A COx > 0.3 was considered as indicative of autoregulation impairment. COx-MAP plots were investigated allowing determining optimal MAP (MAPopt) and limits of autoregulation: lower (LLA) and upper (ULA). Neurological outcome was assessed by the onset of an acute neurological event (ANE) after ECMO start. RESULTS: We included 29 children (median age 84 days, weight 4.8 kg). MAPopt, LLA, and ULA were detected in 90.8% (84.3-93.3) of monitoring time. Mean COx was significantly higher during day 1 of ECMO compared to day 2 [0.1 (0.02-0.15) vs. 0.01 (- 0.05 to 0.1), p = 0.002]. Twelve children experienced ANE (34.5%). The mean COx and the percentage of time spent with a COx > 0.3 were significantly higher among ANE+ compared to ANE- patients [0.09 (0.01-0.23) vs. 0.04 (- 0.02 to 0.06), p = 0.04 and 33.3% (24.8-62.1) vs. 20.8% (17.3-23.7) p = 0.001]. ANE+ patients spent significantly more time with MAP below LLA [17.2% (6.5-32.9) vs. 5.6% (3.6-9.9), p = 0.02] and above ULA [13% (5.3-38.4) vs. 4.2% (2.7-7.4), p = 0.004], respectively. CONCLUSION: CA assessment is feasible in pediatric ECMO. The first 24 h following ECMO represents the most critical period regarding CA. Impaired autoregulation is significantly more severe among patients who experience ANE.
OBJECTIVE: Cerebral autoregulation (CA) impairment may pose a risk factor for neurological complications among children supported by extracorporeal membrane oxygenation (ECMO). Our first objective was to investigate the feasibility of CA continuous monitoring during ECMO treatment and to describe its evolution over time. The second objective was to analyze the association between CA impairment and neurological outcome. DESIGN: Observational prospective study. PATIENTS AND SETTING: Twenty-nine children treated with veno-arterial or veno-venous ECMO in the PICU of Nantes University Hospital, France, and the PICU of the IRCCS Giannina Gaslini Institute in Genoa, Italy. MEASUREMENTS: A correlation coefficient between the variations of regional cerebral oxygen saturation and the variations of mean arterial blood pressure (MAP) was calculated as an index of CA (cerebral oxygenation reactivity index, COx). A COx > 0.3 was considered as indicative of autoregulation impairment. COx-MAP plots were investigated allowing determining optimal MAP (MAPopt) and limits of autoregulation: lower (LLA) and upper (ULA). Neurological outcome was assessed by the onset of an acute neurological event (ANE) after ECMO start. RESULTS: We included 29 children (median age 84 days, weight 4.8 kg). MAPopt, LLA, and ULA were detected in 90.8% (84.3-93.3) of monitoring time. Mean COx was significantly higher during day 1 of ECMO compared to day 2 [0.1 (0.02-0.15) vs. 0.01 (- 0.05 to 0.1), p = 0.002]. Twelve children experienced ANE (34.5%). The mean COx and the percentage of time spent with a COx > 0.3 were significantly higher among ANE+ compared to ANE- patients [0.09 (0.01-0.23) vs. 0.04 (- 0.02 to 0.06), p = 0.04 and 33.3% (24.8-62.1) vs. 20.8% (17.3-23.7) p = 0.001]. ANE+ patients spent significantly more time with MAP below LLA [17.2% (6.5-32.9) vs. 5.6% (3.6-9.9), p = 0.02] and above ULA [13% (5.3-38.4) vs. 4.2% (2.7-7.4), p = 0.004], respectively. CONCLUSION: CA assessment is feasible in pediatric ECMO. The first 24 h following ECMO represents the most critical period regarding CA. Impaired autoregulation is significantly more severe among patients who experience ANE.
Authors: Chiara Robba; Gregorio Santori; Marek Czosnyka; Francesco Corradi; Giuseppe Citerio Journal: Intensive Care Med Date: 2019-11-12 Impact factor: 17.440
Authors: Emmie N Upners; Alexander S Busch; Kristian Almstrup; Jørgen H Petersen; Maria Assens; Katharina M Main; Rikke B Jensen; Anders Juul Journal: Pediatr Res Date: 2020-11-03 Impact factor: 3.756
Authors: Hasan Ayaz; Wesley B Baker; Giles Blaney; David A Boas; Heather Bortfeld; Kenneth Brady; Joshua Brake; Sabrina Brigadoi; Erin M Buckley; Stefan A Carp; Robert J Cooper; Kyle R Cowdrick; Joseph P Culver; Ippeita Dan; Hamid Dehghani; Anna Devor; Turgut Durduran; Adam T Eggebrecht; Lauren L Emberson; Qianqian Fang; Sergio Fantini; Maria Angela Franceschini; Jonas B Fischer; Judit Gervain; Joy Hirsch; Keum-Shik Hong; Roarke Horstmeyer; Jana M Kainerstorfer; Tiffany S Ko; Daniel J Licht; Adam Liebert; Robert Luke; Jennifer M Lynch; Jaume Mesquida; Rickson C Mesquita; Noman Naseer; Sergio L Novi; Felipe Orihuela-Espina; Thomas D O'Sullivan; Darcy S Peterka; Antonio Pifferi; Luca Pollonini; Angelo Sassaroli; João Ricardo Sato; Felix Scholkmann; Lorenzo Spinelli; Vivek J Srinivasan; Keith St Lawrence; Ilias Tachtsidis; Yunjie Tong; Alessandro Torricelli; Tara Urner; Heidrun Wabnitz; Martin Wolf; Ursula Wolf; Shiqi Xu; Changhuei Yang; Arjun G Yodh; Meryem A Yücel; Wenjun Zhou Journal: Neurophotonics Date: 2022-08-30 Impact factor: 4.212
Authors: Yaroslava Longhitano; Francesca Iannuzzi; Giulia Bonatti; Christian Zanza; Antonio Messina; Daniel Godoy; Wojciech Dabrowski; Li Xiuyun; Marek Czosnyka; Paolo Pelosi; Rafael Badenes; Chiara Robba Journal: Front Neurol Date: 2021-11-16 Impact factor: 4.003